A questionnaire survey on the management of Graves' orbitopathy in Europe
- PMID: 16868132
- DOI: 10.1530/eje.1.02201
A questionnaire survey on the management of Graves' orbitopathy in Europe
Abstract
Objective: To determine management patterns among clinicians who treat patients with Graves' orbitopathy (GO) in Europe.
Design and methods: Questionnaire survey including a case scenario of members of professional organisations representing endocrinologists, ophthalmologists and nuclear medicine physicians.
Results: A multidisciplinary approach to manage GO was valued by 96.3% of responders, although 31.5% did not participate or refer to a multidisciplinary team and 21.5% of patients with GO treated by responders were not managed in a multidisciplinary setting. Access to surgery for sight-threatening GO was available only within weeks or months according to 59.5% of responders. Reluctance to refer urgently to an ophthalmologist was noted by 32.7% of responders despite the presence of suspected optic neuropathy. The use of steroids was not influenced by the age of the patient, but fewer responders chose to use steroids in a diabetic patient (72.1 vs 90.5%, P<0.001). Development of cushingoid features resulted in a reduction in steroid use (90.5 vs 36.5%, P<0.001) and increase in the use of orbital irradiation (from 23.8% to 40.4%, P<0.05) and surgical decompression (from 20.9 to 52.9%, P<0.001). More ophthalmologists chose surgical decompression for patients with threatened vision due to optic neuropathy, who were intolerant to steroids than other specialists (70.3 vs 41.8%, P<0.01).
Conclusion: Deficiencies in the management of patients with GO in Europe were identified by this survey. Further training of clinicians, easier access of patients to specialist multidisciplinary centres and the publication of practice guidelines may help improve the management of this condition in Europe.
Similar articles
-
Management of Graves' orbitopathy in Latin America: an international questionnaire study compared with Europe.Clin Endocrinol (Oxf). 2008 Dec;69(6):951-6. doi: 10.1111/j.1365-2265.2008.03289.x. Epub 2008 Apr 29. Clin Endocrinol (Oxf). 2008. PMID: 18462263
-
[Management of Graves' orbitopathy: evidence-based recommendations].Dtsch Med Wochenschr. 2009 Dec;134(49):2521-4. doi: 10.1055/s-0029-1243057. Epub 2009 Nov 25. Dtsch Med Wochenschr. 2009. PMID: 19941237 German.
-
Sight-threatening Graves' orbitopathy: Twenty years' experience of a multidisciplinary thyroid-eye outpatient clinic.Clin Endocrinol (Oxf). 2019 Jan;90(1):208-213. doi: 10.1111/cen.13880. Epub 2018 Nov 19. Clin Endocrinol (Oxf). 2019. PMID: 30339291
-
Optimal management of Graves orbitopathy: a multidisciplinary approach.Neth J Med. 2011 Jul-Aug;69(7):302-8. Neth J Med. 2011. PMID: 21934174 Review.
-
[Thyroid ophthalmopathy at the time of European Group On Graves Orbitopathy (EUGOGO)].Presse Med. 2011 Dec;40(12 Pt 1):1163-73. doi: 10.1016/j.lpm.2011.10.002. Epub 2011 Nov 25. Presse Med. 2011. PMID: 22119334 Review. French.
Cited by
-
Considerations for Use of Immune Checkpoint Inhibitors in Cancer Therapy for Patients with Co-Existing Thyroid Eye Disease.Ophthalmol Ther. 2021 Mar;10(1):5-12. doi: 10.1007/s40123-020-00317-y. Epub 2020 Nov 4. Ophthalmol Ther. 2021. PMID: 33146864 Free PMC article.
-
Teprotumumab versus intravenous methylprednisolone in thyroid eye disease: A systematic review.Oman J Ophthalmol. 2024 Oct 24;17(3):313-319. doi: 10.4103/ojo.ojo_308_23. eCollection 2024 Sep-Dec. Oman J Ophthalmol. 2024. PMID: 39651498 Free PMC article. Review.
-
Short and long-term effects of high-dose intravenous methylprednisolone pulse therapy on thyroid-associated ophthalmopathy.Exp Ther Med. 2016 Aug;12(2):901-908. doi: 10.3892/etm.2016.3446. Epub 2016 Jun 9. Exp Ther Med. 2016. PMID: 27446294 Free PMC article.
-
Thyroid eye disease survey: An anonymous web-based survey in the Indian subcontinent.Indian J Ophthalmol. 2020 Aug;68(8):1609-1614. doi: 10.4103/ijo.IJO_1918_19. Indian J Ophthalmol. 2020. PMID: 32709788 Free PMC article.
-
Diagnosis and management of Graves disease: a global overview.Nat Rev Endocrinol. 2013 Dec;9(12):724-34. doi: 10.1038/nrendo.2013.193. Epub 2013 Oct 15. Nat Rev Endocrinol. 2013. PMID: 24126481 Review.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources